Visanne (dienogest) / Mochida, Bayer - LARVOL DELTA

High inhibition ratio and transformation index of 2 mg dienogest: further evidence for its use in endometriosis treatment. (PubMed, Eur J Contracept Reprod Health Care) - "Recently, the inhibition ratio and the transformation index for progestins have been proposed. DNG at the used dose of 2 mg/daily, with a transformation index of around 933% and a cyclical inhibition ratio of 200%, appears to have very specific progestin properties, unique among different molecules of the same groups, reinforcing its leading role in the treatment of endometriosis."

Journal • Endometriosis • Gynecology • Pain • Women's Health

Therapeutic efficacy of dienogest combined with GnRH agonist in adenomyosis and associated obstetric risk factors: A meta-analysis. (PubMed, Medicine (Baltimore)) - "Additionally, 11 studies with 15,015 participants analyzed obstetric risk factors, revealing that women with adenomyosis had significantly higher risks of spontaneous abortion, premature rupture of membranes, preterm birth, small-for-gestational-age fetuses, and cesarean section. These findings suggest that dienogest combined with GnRH-a can improve therapeutic outcomes for adenomyosis, while also highlighting increased obstetric risks associated with the condition."

Clinical • Journal • Retrospective data • Review • Endometriosis • Obstetrics • Small for Gestational Age • Women's Health

The role of pharmacotherapy in the treatment of endometriosis: an update. (PubMed, Expert Opin Pharmacother) - "First-line therapies, including NSAIDs, combined oral contraceptives, and progestins such as dienogest, remain central, while GnRH agonists/antagonists and aromatase inhibitors are considered in refractory cases...Ongoing clinical trials, artificial intelligence - assisted diagnostics, and fertility-focused pharmacotherapies represent exciting frontiers. Multimodal, patient-tailored approaches will be key to optimizing long-term outcomes in endometriosis management."

Journal • Review • Endometriosis • Gynecology • Infertility • Pain • Sexual Disorders • Women's Health

Efficacy of Dienogest Versus GnRH Agonists After Endometriosis Surgery: A Systematic Review and Meta-Analysis. (PubMed, J Minim Invasive Gynecol) - "This meta-analysis shows that DNG and GnRH agonists demonstrate comparable efficacy in postoperative pain management and lesion recurrence after laparoscopic endometriosis excision. These findings, however, should be interpreted with caution due to the high risk of bias of the included studies. DNG appears to be more frequently associated with vaginal bleeding, whereas GnRH agonists are more often linked to hot flushes."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Screening and prioritization of endocrine-disrupting chemicals in plastic toys for children based on non-target analysis and machine learning predictive model. (PubMed, Environ Int) - "The antibacterial agent ethyl sorbate, antioxidant Irganox 1010, therapeutics/prescription drugs dienogest, and antibacterial agent chalcone were identified as top priority EDCs in each material. This study highlights the urgent need to assess the exposure risks for infants through plastic toys and to implement control measures for emerging EDCs in plastic toys for very young children."

Journal • Infectious Disease

A Novel Method of "Pre-fabricated Knot" Hysteroscopic Levonorgestrel-releasing Intrauterine System Suture Fixation. (PubMed, Fertil Steril) - "The technique offers equal efficacy, reduced operative time, and enhanced safety due to its simplified procedural steps. However, its indication should currently be limited to adenomyosis patients with anemia, dysmenorrhea and menorrhagia, particularly those with a history of intrauterine device expulsion. Future studies with extended follow-up periods and larger patient cohorts are warranted to further evaluate the long-term outcomes of this technique."

Journal • Endometriosis • Gynecology • Hematological Disorders • Long-acting Reversible Contraceptives • Women's Health

Case Report: Long-term maintenance of GnRH-a combined with dienogest for thoracic endometriosis syndrome. (PubMed, Front Med (Lausanne)) - "In this paper we have collected the clinical data of two patients with thoracic endometriosis syndrome, both of whom presented with haemoptysis as the first symptom and had a history of endometriosis. After 6 courses of treatment with gonadotropin-releasing hormone analogues followed by maintenance treatment with dienogest, the patients' haemoptysis symptoms were relieved, the CT lesions in the lungs were significantly resorbed compared with the previous ones, and no recurrence was observed at long-term follow-up."

Journal • Endometriosis • Gynecology • Women's Health

OPTIMIZING FERTILITY OUTCOMES: THE SYNERGISTIC ROLE OF GONADOTROPIN-RELEASING HORMONE AGONIST AND DIENOGEST IN ADENOMYOSIS MANAGEMENT DURING FET CYCLES IN IVF/ICSI – A RETROSPECTIVE COHORT STUDY (ASRM 2025) - No abstract available

Retrospective data • Endometriosis • Women's Health

LETROZOLE VS. DIENOGEST FOR ADENOMYOSIS TREATMENT, RANDOMIZED CONTROLLED TRIAL (ASRM 2025) - No abstract available

Clinical • Endometriosis • Women's Health

LONG-TERM DIENOGEST THERAPY FOR ENDOMETRIOSIS: A PROSPECTIVE COHORT STUDY ON PAIN, QUALITY OF LIFE, AND BLEEDING PATTERNS IN IRANIAN WOMEN (ASRM 2025) - No abstract available

Clinical • HEOR • Endometriosis • Gynecology • Pain • Women's Health

Gene Expression Profiling and Pathway Analysis of the Effect of Dienogest on Ovarian Endometriosis: A Comparative Study. (PubMed, Yonsei Med J) - "Comparison of the dienogest-treated and untreated groups before endometriotic ovarian cyst surgery revealed pathways related to immune system function, inflammatory response, cell signaling and adhesion, and metabolic regulation. These findings suggest that dienogest may play a role in controlling inflammation and immune regulation, potentially alleviating endometriosis-related symptoms and delaying recurrence. Although further studies are required for validation, our preliminary findings suggest that dienogest may contribute to delaying the progression from endometriosis to carcinoma."

Clinical • Journal • Endometriosis • Gynecology • Inflammation • Oncology • Women's Health

Acute Admissions in Endometriosis: Patterns, Risk-factors, and management at a Tertiary Gynaecological Centre (ESGE 2025) - "Prior hormonal therapy was absent in 47% of total admissions, whereas Dienogest and LNG-containing Mirena IUD were the most frequently used hormonal treatments among those with pain exacerbations...Conclusions This analysis highlights key associations between clinical presentations of acute endometriosis admissions, management strategies, and patient-specific factors, including BMI, ethnicity, hormonal treatments, fertility interventions, and menstrual cycle phases. These findings provide valuable insights to support improved risk stratification, patient counselling and to develop targeted preventive and management strategies in acute endometriosis care."

Clinical • Endometriosis • Gynecology • Long-acting Reversible Contraceptives • Women's Health

How do large endometriomas respond to medical treatment with dienogest? (ESGE 2025) - "Prolonged progestin therapy represents a valuable non-invasive alternative to surgery, particularly for patients seeking ovarian preservation or at high surgical risk. These findings support the use of dienogest as a frontline conservative option in the management of large endometriomas."

Endometriosis • Gynecology • Women's Health

Comparison between Levonorgestrel-releasing intrauterine device and Dienogest for Adenomyosis: A systematic review with meta-analysis. (PubMed, J Obstet Gynaecol Can) - "Both LNG-IUS and DNG are both useful for managing adenomyosis, though they exhibit different therapeutic effects. LNG-IUS helps in decreasing UV, whereas DNG more notably alleviates dysmenorrhea. Despite these findings, only nine studies were included in this meta-analysis, calling for further large-scale, randomized controlled trials to compare these interventions' efficacy and to develop robust, evidence-based treatment protocols."

Journal • Retrospective data • Review • Endometriosis • Long-acting Reversible Contraceptives • Women's Health

Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial. (PubMed, Adv Ther) - "This study did not demonstrate statistical non-inferiority of 1-mg/day DNG treatment over 2-mg/day DNG treatment for pain relief. These results suggest that the 2-mg/day dose may offer more robust analgesic effects, particularly during the early treatment phase. However, 1-mg/day DNG still showed meaningful symptom improvement with fewer adverse events than 2-mg/day DNG, supporting its potential use in selected patients requiring long-term therapy. Trial Registration Japan Registry of Clinical Trials, trial registration number: jRCTs041210016."

Journal • Endometriosis • Gynecology • Pain • Women's Health

Efficacy of Organic Selenium Supplementation on Endometrioma Regression and Pain in Women With Endometriosis: A Triple-Blind Randomized Controlled Clinical Trial. (PubMed, Biol Trace Elem Res) - "Using block randomization with block sizes of 4 or 6, participants were assigned (1:1 ratio) to receive either one 200-mcg capsule of organic selenium or an identical placebo along with routine treatment (2 mg of verojest (dienogest) daily for 3 months)...Our findings support the hypothesis that organic selenium supplementation may present a promising adjuvant therapy to reduce the size of endometriomas and alleviate various painful symptoms associated with endometriosis, including dysmenorrhea, dyspareunia, dysuria, non-cyclic pain, and dyschezia. ClinicalTrial.gov Identifier: IRCT20110606006709N26."

Clinical • Journal • Endometriosis • Gynecology • Obstetrics • Pain • Women's Health

Comparison of the short-term effects of dienogest and oral contraceptives on pain and quality of life in women with endometriosis: a systematic review and meta-analysis. (PubMed, BMC Womens Health) - "Dienogest is superior to OCPs in improving pain and QoL in patients with endometriosis, but not as effective as OCPs in pelvic pain and dyspareunia, and the safety was similar between the two types of drugs."

Clinical • HEOR • Journal • Retrospective data • Review • Back Pain • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

THE NAPCSR, THE BIOMARKER FOR CHC-ASSOCIATED THROMBOTIC RISK EVALUATION (FIGO 2025) - " nAPCsr was assessed on plasma samples from women using either no contraception (n = 220), progestin-only pill (POP) (n = 14), natural estrogen (estradiol or estetrol)-based CHC (n = 43), ethinylestradiol (EE) 20 or 30 μg with levonorgestrel (n = 70), EE 20 μg with desogestrel, gestodene or drospirenone (n = 105) and EE ≥30 μg with desogestrel, dienogest or cyproterone acetate (n = 32). For non-users or women using POP, nAPCsr >3.0 indicate a procoagulable state, which could be attributable to thrombophilia (e.g. FV Leiden), meaning the pill should be contraindicated. For women already on CHCs, nAPCsr above respective thresholds indicate that the benefit–risk balance of the contraceptive formulation used is questionable."

Biomarker • Hematological Disorders • Hepatitis C

Tackling rare site endometriosis (FIGO 2025) - "Planned to give tab dienogest 2 mg for next 6 months.and follow her up... Thoracic endometriosis is a rare condition with respiratory symptoms like Sob, chest pain, cough, and collapsed lung unrelated to menstruation delaying diagnosis. Diagnostic modalities are chest X-rays CT scans MRIs and Thoracoscopy. The gold standard for diagnosis is Trusted Source video-assisted thoracic surgery (VATS)."

Cough • Endometriosis • Gynecology • Respiratory Diseases • Women's Health

Polycystic ovary syndrome and estroprogestins. (PubMed, Minerva Obstet Gynecol) - "In conclusion, an aware choice of the most adequate and tolerable EP formulation according to the pharmacological profile and individual characteristics of PCOS patient is essential to opportunely customize the treatment of androgen excess."

Journal • Acne Vulgaris • Alopecia • Genetic Disorders • Immunology • Obesity • Polycystic Ovary Syndrome • Seborrheic Dermatitis • Women's Health

TAEDIUMVITAE: Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis (clinicaltrials.gov) - P=N/A | N=138 | Active, not recruiting | Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

New trial • Endometriosis • Gynecology • Women's Health

Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam. (PubMed, Cost Eff Resour Alloc) - "Dienogest is a cost-effective alternative to GnRH-a drugs for treating dysmenorrhea and pelvic pain in Vietnam, offering improved health outcomes at a lower cost. These findings support its broader adoption in clinical practice and healthcare policy."

HEOR • Journal • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Impact of endometrioma management strategies on ovarian reserve over the follow-up period, a prospective longitudinal study. (PubMed, Front Endocrinol (Lausanne)) - P=N/A | "Treatment with both dienogest and OCP is associated with a decrease in serum AMH levels, although the decline appears less significant with dienogest. Patients managed expectantly also showed a progressive decline in ovarian reserve compared to healthy controls.Trial Registration Number: Clinical Trials, NCT03620838."

Journal • Observational data • Endometriosis • Gynecology • Women's Health

Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis. (PubMed, BJOG) - "LNG-IUS combined with laparoscopic surgery appears most effective in reducing recurrence and pain in EMs patients. Danazol and goserelin should be used cautiously due to notable adverse effects."

Journal • Retrospective data • Review • Endometriosis • Gynecology • Pain • Women's Health

Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain. (PubMed, Biomedicines) - "Objectives: This review critically synthesises the evidence for the three main hormonal therapies-gonadotropin-releasing hormone (GnRH) analogues, dienogest, and gestrinone-focusing on their distinct tolerability and safety profiles to inform this modern clinical framework... In the absence of a clear hierarchy of efficacy, the optimal therapeutic choice is not determined by potency, but by a collaborative process in which patient values and tolerance for specific adverse effects guide selection. This review provides a framework to facilitate this shared decision-making (SDM) in clinical practice."

Journal • Review • Cardiovascular • CNS Disorders • Endometriosis • Gynecology • Musculoskeletal Pain • Osteoporosis • Pain • Women's Health